Strong Presence at National Professional Diabetes Congresses in
the UK, France and Germany Demonstrates Insulet’s Commitment to the
European Diabetes Community
BILLERICA, Mass.--(BUSINESS WIRE)--Mar. 14, 2018--
Insulet Corporation (NASDAQ:PODD) (Insulet or the Company), the leader
in tubeless
insulin pump technology with its Omnipod® Insulin
Management System (Omnipod System), announced that it will have a strong
presence at three leading national diabetes congresses in Europe over
the coming months:
- Diabetes UK Professional Conference (Diabetes UK), March 14-16 at
ExCeL, London
-
Société Francophone du Diabète (SFD) Annual Conference, March 20-23 at
Cité des Congrès de Nantes, France
-
Deutsche Diabetes Gesellschaft (DDG) Diabetes Kongress, May 9-12 at
CityCube Berlin, Germany
Insulet will have a booth presence at each meeting to allow its
fast-growing European team to interact directly with the diabetes
community. Additionally, at Diabetes UK, Insulet will hold a sponsored
symposium, “The Omnipod Insulin Management System: Real-world use and
future innovation” on Thursday, March 15, in Room 1 from 6:35–7:35 p.m.
(local time). Healthcare professionals attending these congresses will
also have the opportunity take the “Pod Challenge” to experience
first-hand the simplicity and ease of use that the OmnipodSystem
offers users globally.
The Company’s presence at these major European meetings will provide a
platform for the local Insulet teams to more broadly communicate the
Company’s plans to transition to direct operations in Europe to
distribute and support its Omnipod System on July 1, 2018. The latest
news about the transition in Europe is available at https://www.omnipodeurope.com.
“We are excited to attend these important national congresses and
support the diabetes communities in Europe,” said Patrick Sullivan,
Chairman and Chief Executive Officer. “We are confident our local teams
have the experience and talent necessary to transition this business
successfully and to drive increased value for our customers and all of
our stakeholders.”
About the Omnipod Insulin Management System:
The Omnipod Insulin Management System is an innovative continuous
insulin delivery system that provides all the proven benefits of
continuous subcutaneous insulin infusion (CSII) therapy in a way no
conventional insulin pump can. The Omnipod System's innovative design
and features allows people living with diabetes to live their life—and
manage their diabetes—with unprecedented freedom, comfort, convenience,
and ease. The Omnipod System consists of two components: (i) a Pod that
stores and delivers insulin; and (ii) a Personal Diabetes Manager (PDM)
that wirelessly programs the user's personalized insulin delivery,
calculates suggested doses and insulin on board, and has a convenient,
built-in blood glucose meter. The small, light-weight Pod can be worn in
multiple locations, including the abdomen, hip, back of upper arm, upper
thigh or lower back and, because it is waterproof (IPX8), there is no
need to remove when showering, swimming or performing other activities.
This means that Omnipod can provide up to three days of non-stop insulin
delivery, without the need to disconnect a tube set or manually inject
insulin. The Pod and PDM communicate wirelessly to offer precise,
personalized and continuous insulin delivery with customizable basal and
bolus delivery options, as well as important safety checks. The Pod's
auto-cannula insertion is quick, simple, and virtually pain-free. Users
never have to handle a needle. The user simply pushes a button on the
PDM and the Pod's automated insertion system inserts the cannula beneath
the skin and begins delivering insulin according to the user's
programmed basal rate.
The Omnipod System is the world's first commercially available tubeless
insulin delivery system that allows users to live untethered by tubing
and without the stress and anxiety of multiple daily injections. By
breaking down the barriers to insulin pump therapy, the Omnipod System
offers freedom for users to live life on their own terms and with the
ease of use they deserve.
About Insulet Corporation:
Insulet Corporation (NASDAQ: PODD), headquartered in Massachusetts, is
an innovative medical device company dedicated to making the lives of
people with diabetes and other conditions easier through the use of its
Omnipod product platform. The Omnipod Insulin Management System provides
a unique alternative to traditional insulin delivery methods. With its
simple, wearable design, the disposable Pod provides up to three days of
non-stop insulin delivery, without the need to see or handle a needle.
Insulet also leverages the unique design of its Pod, by tailoring its
Omnipod technology platform for the delivery of non-insulin subcutaneous
drugs across multiple therapeutic areas. Founded in 2000, more than
140,000 users across the globe rely on Insulet’s Omnipod Insulin
Management System to bring simplicity and freedom to their lives. For
more information, please visit: www.insulet.com,
www.myomnipod.com
and https://www.omnipodeurope.com.*
*Starting July 1, 2018, Insulet will assume direct distribution of its
Omnipod Insulin Management System in Europe, including sales, marketing,
training and customer support activities. This will allow Insulet to be
closer to the diabetes community and identify opportunities to support
European customer needs over the long-term, as it already does in the
United States and Canada.
Forward-Looking Statement:
This press release may contain forward-looking statements concerning
Insulet's expectations, anticipations, intentions, beliefs or strategies
regarding the future. These forward-looking statements are based on its
current expectations and beliefs concerning future developments and
their potential effects on Insulet. There can be no assurance that
future developments affecting Insulet will be those that it has
anticipated. These forward-looking statements involve a number of risks,
uncertainties (some of which are beyond its control) or other
assumptions that may cause actual results or performance to be
materially different from those expressed or implied by these
forward-looking statements, and other risks and uncertainties described
in its Annual Report on Form 10-K, which was filed with the Securities
and Exchange Commission on February 22, 2018 in the section entitled
"Risk Factors," and in its other filings from time to time with the
Securities and Exchange Commission. Should one or more of these risks or
uncertainties materialize, or should any of its assumptions prove
incorrect, actual results may vary in material respects from those
projected in these forward-looking statements. Insulet undertakes no
obligation to publicly update or revise any forward-looking statements.
View source version on businesswire.com: http://www.businesswire.com/news/home/20180314005258/en/
Source: Insulet Corporation
Insulet Corporation
Investor Relations and Corporate
Media:
Deborah R. Gordon, 978-600-7717
Vice President,
Investor Relations and Corporate Communications
dgordon@insulet.com
or
International
Media:
Dominic Hulton, +44 20 3941 5374
Vice
President, Marketing, Europe
dhulton@insulet.com
